Rhumbline Advisers Ultragenyx Pharmaceutical Inc. Transaction History

Rhumbline Advisers

  • $105 Billion
  • Q2 2024

A detailed history of Rhumbline Advisers transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 96,710 shares of RARE stock, worth $4.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,710
Previous 91,663 5.51%
Holding current value
$4.88 Million
Previous $4.28 Million 7.13%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
BUY
$37.42 - $51.61 $188,858 - $260,475
5,047 Added 5.51%
96,710 $3.97 Million
Q1 2024

May 09, 2024
SELL
$43.02 - $53.69 $387,266 - $483,317
-9,002 Reduced 8.94%
91,663 $4.28 Million
Q4 2023

Feb 08, 2024
BUY
$31.73 - $49.19 $255,426 - $395,979
8,050 Added 8.69%
100,665 $4.81 Million
Q3 2023

Nov 09, 2023
SELL
$34.92 - $46.66 $14,736 - $19,690
-422 Reduced 0.45%
92,615 $3.3 Million
Q2 2023

Aug 08, 2023
BUY
$37.35 - $52.15 $463,364 - $646,972
12,406 Added 15.39%
93,037 $4.29 Million
Q1 2023

May 11, 2023
BUY
$36.99 - $48.71 $173,039 - $227,865
4,678 Added 6.16%
80,631 $3.23 Million
Q4 2022

Feb 14, 2023
BUY
$33.72 - $46.33 $89,762 - $123,330
2,662 Added 3.63%
75,953 $3.52 Million
Q3 2022

Nov 10, 2022
BUY
$39.96 - $66.14 $75,804 - $125,467
1,897 Added 2.66%
73,291 $3.04 Million
Q2 2022

Aug 11, 2022
BUY
$45.8 - $85.4 $221,672 - $413,336
4,840 Added 7.27%
71,394 $4.26 Million
Q1 2022

May 12, 2022
SELL
$62.2 - $84.4 $254,522 - $345,364
-4,092 Reduced 5.79%
66,554 $4.83 Million
Q4 2021

Feb 10, 2022
BUY
$73.71 - $87.86 $32,137 - $38,306
436 Added 0.62%
70,646 $5.94 Million
Q3 2021

Nov 12, 2021
SELL
$77.92 - $102.4 $143,294 - $188,313
-1,839 Reduced 2.55%
70,210 $6.33 Million
Q2 2021

Aug 05, 2021
SELL
$92.19 - $115.71 $532,673 - $668,572
-5,778 Reduced 7.42%
72,049 $6.87 Million
Q1 2021

May 06, 2021
SELL
$106.9 - $167.73 $788,494 - $1.24 Million
-7,376 Reduced 8.66%
77,827 $8.86 Million
Q4 2020

Feb 10, 2021
BUY
$84.4 - $177.39 $659,839 - $1.39 Million
7,818 Added 10.1%
85,203 $11.8 Million
Q3 2020

Nov 12, 2020
SELL
$72.98 - $90.0 $1.12 Million - $1.38 Million
-15,320 Reduced 16.53%
77,385 $6.36 Million
Q2 2020

Aug 13, 2020
BUY
$46.91 - $78.22 $337,611 - $562,949
7,197 Added 8.42%
92,705 $7.25 Million
Q1 2020

May 06, 2020
BUY
$33.8 - $62.9 $49,280 - $91,708
1,458 Added 1.73%
85,508 $3.8 Million
Q4 2019

Feb 05, 2020
BUY
$36.08 - $45.83 $123,357 - $156,692
3,419 Added 4.24%
84,050 $3.59 Million
Q3 2019

Oct 23, 2019
SELL
$42.5 - $63.11 $57,970 - $86,082
-1,364 Reduced 1.66%
80,631 $3.45 Million
Q2 2019

Aug 14, 2019
BUY
$54.93 - $74.36 $394,287 - $533,756
7,178 Added 9.59%
81,995 $5.21 Million
Q1 2019

May 01, 2019
BUY
$39.87 - $69.36 $369,036 - $641,996
9,256 Added 14.12%
74,817 $5.19 Million
Q4 2018

Jan 31, 2019
BUY
$38.89 - $77.3 $896,064 - $1.78 Million
23,041 Added 54.19%
65,561 $2.85 Million
Q3 2018

Nov 07, 2018
SELL
$71.81 - $90.15 $176,221 - $221,228
-2,454 Reduced 5.46%
42,520 $3.25 Million
Q2 2018

Aug 06, 2018
BUY
$48.54 - $85.31 $188,869 - $331,941
3,891 Added 9.47%
44,974 $3.46 Million
Q1 2018

May 02, 2018
BUY
$44.33 - $58.52 $110,692 - $146,124
2,497 Added 6.47%
41,083 $2.1 Million
Q4 2017

Feb 09, 2018
SELL
$43.54 - $57.32 $335,562 - $441,765
-7,707 Reduced 16.65%
38,586 $1.79 Million
Q3 2017

Nov 06, 2017
BUY
$49.79 - $66.32 $2.3 Million - $3.07 Million
46,293
46,293 $2.47 Million

Others Institutions Holding RARE

# of Institutions
292
Shares Held
88.4M
Call Options Held
535K
Put Options Held
198K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.53B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email